


The Fund will seek to achieve an above average rate of income combined with sound prospects for capital growth.
| Name | % Net Assets |
|---|---|
| GlaxoSmithKline PLC | 6.7% |
| GlaxoSmithKline PLC | 6.6% |
| BP PLC | 6.2% |
| Royal Dutch Shell PLC | 5.4% |
| Legal & General Group PLC | 5.3% |
| Reed Elsevier PLC | 4.9% |
| Imperial Tobacco Group PLC | 4.5% |
| Unilever PLC | 4.4% |
| Imperial Tobacco Group PLC | 3.9% |
| DS Smith PLC | 3.6% |
| Key | % Net Assets |
|---|---|
| 6.7% | |
| 6.6% | |
| 6.2% | |
| 5.4% | |
| 75.1% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 70.64p |
| Currency | GBP |
| Change | 0.25p |
| % | 0.36% |
| YTD change | 5.01p |
| YTD % | 7.63% |
| Fund Inception | 08/05/2006 |
|---|---|
| Fund Manager | Leigh Harrison |
| TER | 1.63 (30-Mar-2012) |
| Minimum Investment | |
|---|---|
| Initial | £2000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 3.75% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research